Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APC | P25054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10437933 | 0.94 | NOD1 (0.44) | NOD1ECE1OPRM1OPRD1GLO1 | |
| SCHEMBL10437934 | 0.94 | NOD1 (0.44) | NOD1ECE1OPRM1OPRD1GLO1 | |
| SCHEMBL31571919 | 0.93 | NOD1 (0.44) | NOD1ECE1GLO1BMP1PTGS1 | |
| SCHEMBL29352968 | 0.92 | FOLH1 (0.41) | NOD1NMT2NMT1GLO1PTGS1 | |
| SCHEMBL31332141 | 0.92 | FOLH1 (0.41) | NOD1NMT2NMT1GLO1PTGS1 | |
| SCHEMBL10646369 | 0.90 | NOD1 (0.49) | NOD1NMT2NMT1OPRM1OPRD1 | |
| SCHEMBL10646360 | 0.90 | NOD1 (0.49) | NOD1NMT2NMT1OPRM1OPRD1 | |
| SCHEMBL29574819 | 0.89 | NOD1 (0.42) | NOD1ECE1TASP1KMT2A | |
| SCHEMBL30563321 | 0.85 | NOD1 (0.41) | NOD1OPRM1OPRD1GLO1OPRK1 | |
| SCHEMBL30882784 | 0.85 | NMT1 (0.49) | NMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865857-B2 | Medical device with predefined activated cellular integration | SOFRADIM PRODUCTION (FR) | 2014-10-21 | — | — | US | claimed |
| US-4732155-A | Implantable chemoattractant system | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1988-03-22 | — | — | US | claimed |
| US-8865857-B2 | Medical device with predefined activated cellular integration | SOFRADIM PRODUCTION (FR) | 2014-10-21 | — | — | US | disclosed |
| US-20130143976-A1 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | SOFRADIM PRODUCTION (FR) | 2013-06-06 | — | — | US | disclosed |
| EP-2588153-A2 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | Sofradim Production (FR) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012001532-A2 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | SOFRADIM PRODUCTION (FR) | 2012-01-05 | — | — | WO | disclosed |
| US-4732155-A | Implantable chemoattractant system | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143976-A1 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | CCL2, MIF, C3AR1 | NOD1 1477/4885NMT2 3928/4885NMT1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.